Literature DB >> 25586204

The impact of lymph node size to predict nodal metastasis in patients with rectal cancer after preoperative chemoradiotherapy.

Im-Kyung Kim1, Jeonghyun Kang, Beom Jin Lim, Seung-Kook Sohn, Kang Young Lee.   

Abstract

PURPOSE: During restaging after preoperative chemoradiotherapy (CRT), the assessment of lymph node (LN) metastasis is vital for selecting further treatment strategies. This study aimed to evaluate the impact of LN size to predict LN metastasis in rectal cancer patients after preoperative CRT.
METHODS: A total of 30 consecutive patients who underwent preoperative CRT followed by curative resection of primary rectal cancer were selected as a study group (CRT group). As a control group (non-CRT group), 30 patients who underwent primary tumor resection were selected using a 1:1 case-match design. Matching criteria were gender, age, and clinical T stage. The size of each LN was measured from the surgical specimen. To clarify optimal cutoff values for node size according to the risk of detecting metastasis, receiving-operator characteristic (ROC) curves were generated.
RESULTS: In the non-CRT group, 39/474 LNs were confirmed to have metastasis. In the CRT group, 29/422 LNs showed metastasis. The median size of metastatic LNs was 6.0 mm in CRT group, which was significantly larger than 4.0 mm in the non-CRT group (p = 0.006). The optimal cutoff value for determining metastasis in the CRT group was 4.5 mm, compared to 3.5 mm in the non-CRT group. The accuracy of the cutoff value was much higher in the CRT group (CRT vs. non-CRT, 77.9 vs. 59.9%).
CONCLUSIONS: LN size is a strong indicator for prediction of regional LN metastasis in rectal cancer patients after preoperative CRT, compared to those without CRT.

Entities:  

Mesh:

Year:  2015        PMID: 25586204     DOI: 10.1007/s00384-014-2099-0

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  31 in total

1.  Comparative study of transrectal ultrasonography, pelvic computerized tomography, and magnetic resonance imaging in preoperative staging of rectal cancer.

Authors:  N K Kim; M J Kim; S H Yun; S K Sohn; J S Min
Journal:  Dis Colon Rectum       Date:  1999-06       Impact factor: 4.585

2.  Improved survival with preoperative radiotherapy in resectable rectal cancer.

Authors:  B Cedermark; M Dahlberg; B Glimelius; L Påhlman; L E Rutqvist; N Wilking
Journal:  N Engl J Med       Date:  1997-04-03       Impact factor: 91.245

3.  Endorectal ultrasonography for the assessment of wall invasion and lymph node metastasis in rectal cancer.

Authors:  Y Katsura; K Yamada; T Ishizawa; H Yoshinaka; H Shimazu
Journal:  Dis Colon Rectum       Date:  1992-04       Impact factor: 4.585

4.  The size of regional lymph nodes does not correlate with the presence or absence of metastasis in lymph nodes in rectal cancer.

Authors:  H Kotanagi; T Fukuoka; Y Shibata; T Yoshioka; O Aizawa; Y Saito; G E Tur; K Koyama
Journal:  J Surg Oncol       Date:  1993-12       Impact factor: 3.454

5.  Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer.

Authors:  Salvatore Pucciarelli; Carlo Capirci; Urso Emanuele; Paola Toppan; Maria Luisa Friso; Gian Maria Pennelli; Giovanni Crepaldi; Lara Pasetto; Donato Nitti; Mario Lise
Journal:  Ann Surg Oncol       Date:  2005-02-04       Impact factor: 5.344

6.  Prospective comparison of endorectal ultrasound, three-dimensional endorectal ultrasound, and endorectal MRI in the preoperative evaluation of rectal tumors. Preliminary results.

Authors:  M Hünerbein; W Pegios; B Rau; T J Vogl; R Felix; P M Schlag
Journal:  Surg Endosc       Date:  2000-11       Impact factor: 4.584

7.  The potential of restaging in the prediction of pathologic response after preoperative chemoradiotherapy for rectal cancer.

Authors:  Isacco Maretto; Fabio Pomerri; Salvatore Pucciarelli; Claudia Mescoli; Enrico Belluco; Simona Burzi; Massimo Rugge; Pier Carlo Muzzio; Donato Nitti
Journal:  Ann Surg Oncol       Date:  2006-12-02       Impact factor: 5.344

8.  Preoperative lymph node staging in rectal cancer: a difficult challenge.

Authors:  R J Detry; A H Kartheuser; G Lagneaux; J Rahier
Journal:  Int J Colorectal Dis       Date:  1996       Impact factor: 2.571

9.  Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.

Authors:  Mark S Roh; Linda H Colangelo; Michael J O'Connell; Greg Yothers; Melvin Deutsch; Carmen J Allegra; Morton S Kahlenberg; Luis Baez-Diaz; Carol S Ursiny; Nicholas J Petrelli; Norman Wolmark
Journal:  J Clin Oncol       Date:  2009-09-21       Impact factor: 44.544

10.  Evaluating mesorectal lymph nodes in rectal cancer before and after neoadjuvant chemoradiation using thin-section T2-weighted magnetic resonance imaging.

Authors:  Dow-Mu Koh; Ian Chau; Diana Tait; Andrew Wotherspoon; David Cunningham; Gina Brown
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-12-31       Impact factor: 7.038

View more
  3 in total

1.  Assessment of remaining tumour involved lymph nodes with MRI in patients with complete luminal response after neoadjuvant treatment of rectal cancer.

Authors:  Per Loftås; Margrét Sturludóttir; Olof Hallböök; Karin Almlöv; Gunnar Arbman; Lennart Blomqvist
Journal:  Br J Radiol       Date:  2018-05-10       Impact factor: 3.039

2.  Improved detection of a tumorous involvement of the mesorectal fascia and locoregional lymph nodes in locally advanced rectal cancer using DCE-MRI.

Authors:  Marco Armbruster; Melvin D'Anastasi; Veronika Holzner; Martin E Kreis; Olaf Dietrich; Bernhard Brandlhuber; Anno Graser; Martina Brandlhuber
Journal:  Int J Colorectal Dis       Date:  2018-05-17       Impact factor: 2.571

3.  Preoperative chemoradiotherapy changes the size criterion for predicting lateral lymph node metastasis in lower rectal cancer.

Authors:  Yusuke Yamaoka; Yusuke Kinugasa; Akio Shiomi; Tomohiro Yamaguchi; Hiroyasu Kagawa; Yushi Yamakawa; Masakatsu Numata; Akinobu Furutani
Journal:  Int J Colorectal Dis       Date:  2017-07-31       Impact factor: 2.571

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.